Neurocrine Biosciences (NBIX) EBITDA Margin Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 1,129.00 |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 2.00 |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 59.00 |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | -1,031.00 |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -925.00 |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | -46.00 |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 6,666.00 |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | -4,186.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -46.00 |
| Mar 31, 2026 | 5,091.00 |
| Dec 31, 2025 | 109.00 |
| Sep 30, 2025 | 743.00 |
| Jun 30, 2025 | -25,232.00 |
| Mar 31, 2025 | 312.00 |
| Dec 31, 2024 | 3,426.00 |
| Sep 30, 2024 | 1,451.00 |
| Jun 30, 2024 | 290.00 |
| Mar 31, 2024 | 596.00 |
| Dec 31, 2023 | 21.00 |
| Sep 30, 2023 | 4,545.00 |
| Jun 30, 2023 | -907.00 |
| Mar 31, 2023 | -5,201.00 |
| Dec 31, 2022 | 511.00 |
| Sep 30, 2022 | -1,793.00 |
| Jun 30, 2022 | 25,475.00 |
| Mar 31, 2022 | 7,397.00 |
| Dec 31, 2021 | -2,820.00 |
| Sep 30, 2021 | -2,076.00 |